Evidence map›Paper›PMID 39061230›Full record

ArticleCancers2024

Baseline Blood CD8

Hanneke Kievit, M Benthe Muntinghe-Wagenaar, Wayel H Abdulahad, Abraham Rutgers, Lucie B M Hijmering-Kappelle, Birgitta I Hiddinga, J Fred Ubbels, Robin Wijsman, Marcel J van der Leij, Johan Bijzet and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hanneke KievitDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-7389-7291
M Benthe Muntinghe-WagenaarDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-3785-7406
Wayel H AbdulahadDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-3109-4487
Abraham RutgersDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-1641-6890
Lucie B M Hijmering-KappelleDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Birgitta I HiddingaDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
J Fred UbbelsDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0009-0007-5547-5205
Robin WijsmanDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Marcel J van der LeijDepartment of Laboratory Medicine, Medical Immunology Laboratory, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Johan BijzetDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Harry J M GroenDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-2978-5265
Huib A M KerstjensDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-7705-7927
Anthonie J van der WekkenDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Bart-Jan KroesenDepartment of Laboratory Medicine, Medical Immunology Laboratory, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
T Jeroen N HiltermannDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-0665-2160

Funding

AstraZeneca (Netherlands) ESR 16-12461 / D4191C00075
6 · The paper itself

Abstract

backgroundTumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment.

methodsAn exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (<median PFS). The expression of the T cell activation marker CD69 and intracellular cytokines (IL-2, IFNγ, TNFα) in both CD4

resultsAt baseline, a higher percentage of activated CD8

conclusionBaseline blood CD8

Indexed as

biomarkercytokinesimmune checkpoint inhibitionimmunotherapyliquid biopsyNSCLCT cell function assay

Identifiers

PMID39061230
PMCPMC11275013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.